SPRC News - Candlesense

SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc

TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of t...

Will the merger trigger dilution, changes in ownership structure, or regulatory hurdles that could impact shareholder value? What are the potential synergies or strategic benefits of combining a CNS drug developer with an automotive importer, and how might they influence future earnings? How will the merger affect SciSparc’s valuation and share price in the short term?

Mergers

31 minutes ago

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of th...

Will the merger trigger any changes in the company's capital structure, dilution, or future financing needs that could affect investors? What are the strategic synergies or risks associated with a pharmaceutical company merging with a parallel vehicle importer, and how might this impact the company's core business focus? How will the merger with AutoMax Motors affect SciSparc's valuation and share price in the short term?

Mergers

about 3 hours ago

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therap...

What is the potential impact on SciSparc's pipeline diversification and overall risk profile? How does the announced therapy compare to existing treatments for obesity and high blood sugar in terms of efficacy and safety? Are there any regulatory or safety concerns that could delay or jeopardize the development of the novel combination therapy?

Patents

21 days ago